136 related articles for article (PubMed ID: 36251951)
21. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
[TBL] [Abstract][Full Text] [Related]
22. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of
Shi L; Xu C; Ma Y; Ou Q; Wu X; Lu S; Shao Y; Guo R; Kong J
ESMO Open; 2020 Nov; 5(6):e000985. PubMed ID: 33214226
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
Gao J; Chen JQ; Zhang L; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
[TBL] [Abstract][Full Text] [Related]
27. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract][Full Text] [Related]
28. Next generation sequencing in lung cancer: An initial experience from India.
Gupta P; Saha K; Vinarkar S; Banerjee S; Choudhury SS; Parihar M; Midha D; Mukherjee G; Lingegowda D; Chatterjee S; ArunsinghS M; Shrimali R; Ganguly S; Dabkara D; Biswas B; Mishra DK; Arora N
Curr Probl Cancer; 2020 Jun; 44(3):100562. PubMed ID: 32178863
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation.
Wu Y; Ni J; Chang X; Zhang X; Zhang L
Thorac Cancer; 2020 Jul; 11(7):2051-2055. PubMed ID: 32458584
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients.
Malapelle U; Pilotto S; Reale ML; Passiglia F; Pisapia P; Pepe F; Belluomini L; Galetta D; Cortinovis D; Tiseo M; Passaro A; Seminati D; Pagni F; Parra HS; Migliorino MR; Rocco D; Troncone G; Novello S
Crit Rev Oncol Hematol; 2022 Jan; 169():103536. PubMed ID: 34801697
[TBL] [Abstract][Full Text] [Related]
31. Frequency and types of
Lemine Sow M; El Yacoubi H; Moukafih B; Balde S; Akimana G; Najem S; El Khoyaali S; Abahssain H; Chaibi A; Zeb Khan S; Trapani D; Benzekri A; Ghaouti M; Gamra L; Mestari A; Kettani F; Rahali Y; Mrabti H; Elghissassi I; Errihani H
Tumori; 2021 Aug; 107(4):335-340. PubMed ID: 33079008
[TBL] [Abstract][Full Text] [Related]
32. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S; Curioni-Fontecedro A; Nechushtan H; Shih JY; Liao WY; Gautschi O; Spataro V; Unk M; Yang JC; Lorence RM; Carrière P; Cseh A; Chang GC
J Thorac Oncol; 2018 Dec; 13(12):1897-1905. PubMed ID: 30096481
[TBL] [Abstract][Full Text] [Related]
33. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
34. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
35. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
Leal LF; de Paula FE; De Marchi P; de Souza Viana L; Pinto GDJ; Carlos CD; Berardinelli GN; Miziara JE; da Silva CM; Silva ECA; Pereira R; de Oliveira MA; Scapulatempo-Neto C; Reis RM
Sci Rep; 2019 Mar; 9(1):3209. PubMed ID: 30824880
[TBL] [Abstract][Full Text] [Related]
36. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
Baraibar I; Mezquita L; Gil-Bazo I; Planchard D
Crit Rev Oncol Hematol; 2020 Apr; 148():102906. PubMed ID: 32109716
[TBL] [Abstract][Full Text] [Related]
37. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV
Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409
[TBL] [Abstract][Full Text] [Related]
38. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
[TBL] [Abstract][Full Text] [Related]
39. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
Steeghs EMP; Groen HJM; Schuuring E; Aarts MJ; Damhuis RAM; Voorham QJM; ; Ligtenberg MJL; Grünberg K
Lung Cancer; 2022 May; 167():87-97. PubMed ID: 35461050
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer.
Bu S; Wang R; Pan Y; Yu S; Shen X; Li Y; Sun Y; Chen H
Ann Surg Oncol; 2017 Jan; 24(1):291-297. PubMed ID: 27008586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
